‘Science Speaks’ Discusses Study Findings On Using Dolutegravir-Based Treatments For HIV In Low-Resource Setting

IDSA’s “Science Speaks”: Dolutegravir results in low-resource setting highlight benefits
Antigone Barton, senior editor and writer at “Science Speaks,” discusses findings from a study examining the use of dolutegravir-based treatments for HIV in a low-resource setting. Barton notes, “[F]indings from the first study … show use of the drug to be cost effective, as well as safe and extremely effective in suppressing viral loads quickly and maintaining viral suppression below detectable levels” (9/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.